Anatomy Of An Academic Drug Discovery Program | January 20, 2014 Issue - Vol. 92 Issue 3 | Chemical & Engineering News
Volume 92 Issue 3 | p. 28
Issue Date: January 20, 2014 | Web Date: January 23, 2014

Anatomy Of An Academic Drug Discovery Program

Inventing new medicines inside university walls requires complex funding and a highly collaborative research plan
Department: Business
Keywords: industry-academic alliances, pharmaceuticals, biotech, neuroscience, schizophrenia

To download a PDF of this article, go to

Academic institutions are increasingly formalizing their efforts to discover new drugs, often by establishing centers that bring together researchers and technology from across disciplines. As their ranks grow—the nonprofit Academic Drug Discovery Consortium now counts 94 centers as members—a question arises: What does it really take for an academic institution to invent a viable drug candidate?

To answer that question, C&EN looked at efforts by the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) to develop a series of small molecules to treat brain disorders. That program, ultimately licensed to AstraZeneca, reveals the complexity of assembling the funding and scientific know-how needed to bring an invention to the point that it can be handed off to an experienced drug developer.

The early-2013 deal with AstraZeneca for compounds acting on the M4 muscarinic acetylcholine receptor, a biological target relevant in schizophrenia and Alz­heimer’s disease, was the culmination of eight years of work by the VCNDD team. The team’s research was supported by seven government grants that, along the way, generated 50 publications related to the biology and chemistry of modulating the M1 and M4 receptors.

Such success for an academic drug discovery center is impressive, but few have the resources of VCNDD. Formally established in 2007, the center has grown to include roughly 100 full-time employees. In 2013, VCNDD’s budget topped $20 million, more than half of which came from the National Institutes of Health. Corporate partners—which include AstraZeneca, Johnson & Johnson, and Bristol-Myers Squibb—contributed most of the rest.

VCNDD’s funding stream took years of thoughtful planning and intense teamwork to assemble. Also enabling the work were new grants introduced by NIH and an increased focus by the National Institute of Mental Health to support research that bridges basic science and drug development, according to VCNDD’s director, P. Jeffrey Conn.

Conn says his best advice for universities formalizing their drug discovery efforts is to avoid a contract research model, in which core facilities are available to individual researchers, in favor of a dedicated team of drug hunters. “It really does take a very focused team effort in which every member of the team is intellectually fully invested in—obsessing day and night about—the project,” Conn says. ◾

To download a PDF of this article, go to

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society
Gerry Attrickseeker (January 24, 2014 6:36 PM)
A couple of years ago a survey of academic drug discovery in the US (1) highlighted the fact that most of these efforts were at a very early stage of development. It is nice to see that things are progressing and that patient work at the basic level is paying off with new drug candidates of potentially great significance.

1. Frye S, Crosby M, Edwards T, Juliano R. (2011) US Academic Drug Discovery. Nat Rev Drug Discov. 10(6):409-10

Leave A Comment

*Required to comment